Revolution Medicines (RVMD) Stock Price, Quote, News & History | Benzinga

SPY769.86+0.03%QQQ749.55−0.00%BTC/USD85,144.89+0.48%DIA511.70+0.12%GLD380.52+0.10%TLT77.53+0.06%

Revolution Medicines Inc (RVMD) Stock Price, Quote, News & History

RVMDNASDAQ

Trade with Public

Trade with Public

$206.64

0.750.36%

Last update: Oct 2, 4:20 PM

$206.25

0.360.17%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$205.89

Close

$206.64

Volume / Avg.

1.57M / 1.94M

Day Range

$204.07 - $208.82

52 Wk Range

45.61 - 224.31

Market Cap

$44.21B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

4.76%

Days to Cover

7.24

Recent Revolution Medicines, Inc. News

Why Are 42% of US Cancer Patients Draining Their Life Savings in Two Years? Bernie Sanders Has a $400,000 Answer

Bernie Sanders blasts Big Pharma over $400,000 cancer drugs, warning soaring treatment costs can push patients into financial ruin.

Namrata Sen

SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)

Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has 'dangerously overvalued' the biotech.

Radhika Anilkumar Nadig

Snowflake To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital cut the price

Avi Kapoor

When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges

SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.

Vandana Singh

Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug

Shares of Revolution Medicines are trading higher Thursday morning as a wave of Wall Street firms issued price target increases following the commercial rollout of the company's first-in-class oncology therapy.

Henry Khederian

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-1.58B

Investing Cash Flow (TTM)

-1.21B

Financing Cash Flow (TTM)

3.26B

Free Cash Flow (TTM)

-1.59B

Capital Expenditure (TTM)

-10.64M

Net Change in Cash (TTM)

471.13M

Analyst Trends and Forecast

6

Jun

6

Jul

15

1

Aug

5

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$40.99B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

16.94

Earnings Yield % (TTM)

-4.31%

Earnings Yield % (FWD)

-2.35%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$12.16

Company Debt

Total Debt

$487.43M

LT Debt

$487.43M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$815.44M

Debt to Equity

0.25

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-